Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.64 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.64 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.64 |
| ▸ | DUT | P33316 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21625668 | 1.00 | SLC28A1 (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL733979 | 1.00 | SLC28A1 (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL14790737 | 0.93 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL16979568 | 0.93 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL23710676 | 0.91 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL8642265 | 0.91 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL24782135 | 0.90 | DUT (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL24781265 | 0.90 | DUT (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL6760952 | 0.90 | DUT (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL10391187 | 0.90 | DUT (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241596-A1 | SOLID-PHASE PURIFICATION OF SYNTHETIC NUCLEIC ACID SEQUENCES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-08-08 | — | — | US | disclosed |
| US-8901289-B2 | Preparation of nucleotide oligomer | ST. PHARM CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-20100273999-A1 | Preparation of Nucleotide Oligomer | SAMCHULLY PHARM. CO., LTD. (KR) | 2010-10-28 | — | — | US | disclosed |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| US-6175005-B1 | SINGLE STAGE REACTION FOR BLOCKING HYDROXYL GROUPS ON CYCLIC ETHER BY REACTING WITH DEFINED DIFUNCTIONAL SILICON COMPOUND, WITH DEFINED MONOFUNCTIONAL SILICON GROUP, THEN WITH HYDROFLUORIC ACID IN THE PRESENCE OF A NITROGEN BASE | DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2001-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | SLC28A1 23/4885SLC28A2 9/4885SLC29A1 17/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | SLC28A1 19/4885SLC28A2 8/4885SLC29A1 16/4885 |
| US-20100273999-A1 | Preparation of Nucleotide Oligomer | NUDT1, SAMHD1, ADAR | SLC28A1 74/4885SLC28A2 68/4885SLC29A1 39/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | SLC28A1 22/4885SLC28A2 8/4885SLC29A1 17/4885 |
| US-20190241596-A1 | SOLID-PHASE PURIFICATION OF SYNTHETIC NUCLEIC ACID SEQUENCES | POLR2H, POLR2E, POLB | SLC28A1 1749/4885SLC28A2 1890/4885SLC29A1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.